Johnson & Johnson PE Ratio 2006-2018 | JNJ
Current and historical PE ratio for Johnson & Johnson (JNJ) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Johnson & Johnson (JNJ) as of June 30, 2018 is 16.14.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $92.695B | $76.450B |
| Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pfizer (PFE) | United States | $222.220B | 13.67 |
| Novartis AG (NVS) | Switzerland | $190.657B | 16.36 |
| Merck (MRK) | United States | $168.566B | 15.06 |
| AbbVie (ABBV) | United States | $141.089B | 14.39 |
| Novo Nordisk (NVO) | Denmark | $123.252B | 20.42 |
| Sanofi (SNY) | France | $106.218B | 13.44 |
| GlaxoSmithKline (GSK) | United Kingdom | $103.814B | 14.19 |
| Eli Lilly (LLY) | United States | $96.028B | 19.07 |
| AstraZeneca (AZN) | United Kingdom | $94.148B | 9.86 |
| Bristol-Myers Squibb (BMY) | United States | $92.695B | 18.24 |
